Request Demo
Last update 08 May 2025
INV-1120
Last update 08 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists, modulators |
Mechanism EP4 antagonists(Prostanoid EP4 receptor antagonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with INV-1120CTR20211872
INV-1120在局部晚期/转移性实体瘤患者中的首次人体、开放式、I期（剂量递增）临床试验
[Translation] A first-in-human, open-label, Phase I (dose-escalation) clinical trial of INV-1120 in patients with locally advanced/metastatic solid tumors
NCT04443088
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors
100 Clinical Results associated with INV-1120
Login to view more data
100 Translational Medicine associated with INV-1120
Login to view more data
100 Patents (Medical) associated with INV-1120
Login to view more data
100 Deals associated with INV-1120
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | United States | 26 Jun 2020 | |
| Neoplasm Metastasis | Phase 1 | United States | 26 Jun 2020 | |
| Metastatic Solid Tumor | Preclinical | China | 10 Sep 2021 | |
| Solid tumor | Preclinical | United States | 26 Jun 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
CTR20211872 (ASCO2023) Manual  | Phase 1 | 9 | (ztrkwxbwdb) = pxkbwbhwln jmnevkpxqc (ccvwvdawjv ) View more | Positive | 31 May 2023 | ||
(60mg) | (ztrkwxbwdb) = mdyjguiipl jmnevkpxqc (ccvwvdawjv ) View more | ||||||
NCT04443088 (SITC2022) Manual | Phase 1 | 24 | (qjeereoxkh) = hvbmgigxpo nhdmrtcfiq (ajkzotohqg ) View more | Positive | 01 Nov 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free